Ping Chen
Bristol-Myers Squibb
23 Papers
356 Citations
Ping Chen is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: HIV Protease Inhibitor & Protease. The author has an hindex of 6, co-authored 23 publications.
Chat about Author
Papers
Patent
Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
Bang-Chi Chen,Ping Chen,John Hynes,Peter A. Kiener,Katerina Leftheris,Malinda Longphre,Derek J. Norris,Chennagiri R. Pandit,Steven H. Spergel,John S. Tokarski,Stephen T. Wrobleski,Hong Wu,Rulin Zhao +12 more
- 08 Feb 2001
TL;DR: In this paper, the use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed, and compounds useful as CBR modulators for treating respiratory and non-respiratory leukocyte activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of a and B is nitrogen; and R1-R6 are as defined in the specification, wherein R2 with R5 may form a ring, and/or two R4 groups may form six-membered a
186
A practical method for the preparation of α′-chloroketones of N-carbamate protected-α-aminoacids
Ping Chen,Peter T. W. Cheng,Steven H. Spergel,Robert Zahler,Wang Xuebao,John K. Thottathil,Joel C. Barrish,Polniaszek Richard P +7 more
TL;DR: In this paper, a method for the preparation of α-N-BOC-epoxides from protected amino acid esters based on the Kowalski homologation reaction is described.
63
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
A K Patick,Ronald E. Rose,Jill A. Greytok,Bechtold Clifford M,Mark A. Hermsmeier,Ping Chen,Joel C. Barrish,Robert Zahler,Richard J. Colonno,Pin-Fang Lin +9 more
TL;DR: The level of resistance did not increase following continued passage in increasing concentrations of drug, and the resistant virus retained its drug susceptibility phenotype 34 days after drug withdrawal, according to genotypic analysis.
62
Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.
Ping Chen,Peter T. W. Cheng,M. Alam,B. D. Beyer,G. S. Bisacchi,Tamara Dejneka,A. J. Evans,Jill A. Greytok,Mark A. Hermsmeier,William G. Humphreys,G. A. Jacobs,O. Kocy,P.-F. Lin,K. A. Lis,M. A. Marella,Denis E. Ryono,Amy K. Sheaffer,S. H. Spergel,Chongqing Sun,Joseph A. Tino,Gregory D. Vite,Richard J. Colonno,Robert Zahler,Joel C. Barrish +23 more
TL;DR: It was found that appropriate substitution at the para position of the P1' phenyl group of 1 resulted in the identification of equipotent compounds (10l, 10m, 10n, and 15c) which possess significantly decreased cytotoxicity.
38
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.
Bechtold Clifford M,A K Patick,M. Alam,Jill A. Greytok,Joseph A. Tino,Ping Chen,Eric M. Gordon,Saleem Ahmad,Joel C. Barrish,Robert Zahler +9 more
TL;DR: The potent inhibition of HIV-1 during both acute and chronic infections indicates that these aminodiol compounds are effective anti-HIV-1 compounds.
14